RxDoctor Payments Data

Kendall Wagner, MD

Internal Medicine · Fort Smith, ARNPI 1699091264

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,640 of the $5,957 with a category attached, or 61.1%. Corium, LLC accounts for 77.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $4,092 and has fallen 90.7% since, to $380 in 2025. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,957in general payments, 2019–2025

Across 111 payments — averaging $53.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corium, LLC$5K
  • Kowa Pharmaceuticals America, Inc.$181
  • Mirum Pharmaceuticals, Inc.$142
  • Ironshore Pharmaceuticals Inc.$127
  • Merck$81
  • Amarin Pharma, Inc.$75
  • plus $717 from 18 others

What the payments were for

  • Consulting fees$3,64061%
  • Travel & lodging$57210%
  • Food & beverage$1,74529%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,957 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$6,732
Medicare patients
20
Services billed
99

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rufinamide13$25,423
OzempicSemaglutide24$25,346
JardianceEmpagliflozin14$10,556
Levetiracetam56$3,476
Divalproex Sodium11$3,332
Carbamazepine ErCarbamazepine32$3,274
Glycopyrrolate47$1,865
Baclofen66$1,534
Albuterol Sulfate HfaAlbuterol Sulfate20$1,172
Sucralfate15$1,032
Medroxyprogesterone Acetate20$1,018
Diazepam55$768
Lacosamide19$693
Metoclopramide Hcl31$663
Lactulose23$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$69$25,34624 claims
Boehringer IngelheimJardiance$12$10,55614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →